Epigenetic silencing of MEIS2 in prostate cancer recurrence

BACKGROUND: Current diagnostic and prognostic tools for prostate cancer (PC) are suboptimal, resulting in overdiagnosis and overtreatment of clinically insignificant tumors. Thus, to improve the management of PC, novel biomarkers are urgently needed. RESULTS: In this study, we integrated genome-wide...

Descripción completa

Detalles Bibliográficos
Autores principales: Nørgaard, Maibritt, Haldrup, Christa, Bjerre, Marianne Trier, Høyer, Søren, Ulhøi, Benedicte, Borre, Michael, Sørensen, Karina D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805635/
https://www.ncbi.nlm.nih.gov/pubmed/31640805
http://dx.doi.org/10.1186/s13148-019-0742-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805635/
https://www.ncbi.nlm.nih.gov/pubmed/31640805
http://dx.doi.org/10.1186/s13148-019-0742-x

Ejemplares similares